|
1
|
Kabaria R, Klaassen Z and Terris MK: Renal
cell carcinoma: Links and risks. Int J Nephrol Renovasc Dis.
9:45–52. 2016.PubMed/NCBI
|
|
2
|
Escudier B, Porta C, Schmidinger M,
Rioux-Leclercq N, Bex A, Khoo V, Grünwald V, Gillessen S and
Horwich A; ESMO Guidelines Committee. Electronic address, :
clinicalguidelines@esmo.org: Renal cell carcinoma: ESMO clinical
practice guidelines for diagnosis, treatment and follow-up. Ann
Oncol. 30:706–720. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Malone ER, Oliva M, Sabatini PJ, Stockley
TL and Siu LL: Molecular profiling for precision cancer therapies.
Genome Med. 12:82020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fatehullah A, Tan SH and Barker N:
Organoids as an in vitro model of human development and disease.
Nat Cell Biol. 18:246–254. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Clevers H: Modeling development and
disease with organoids. Cell. 165:1586–1597. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rookmaaker MB, Schutgens F, Verhaar MC and
Clevers H: Development and application of human adult stem or
progenitor cell organoids. Nat Rev Nephrol. 11:546–554. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kapałczyńska M, Kolenda T, Przybyła W,
Zajączkowska M, Teresiak A, Filas V, Ibbs M, Bliźniak R, Łuczewski
Ł and Lamperska K: 2D and 3D cell cultures-a comparison of
different types of cancer cell cultures. Arch Med Sci. 4:910–919.
2018.PubMed/NCBI
|
|
8
|
Broutier L, Mastrogiovanni G, Verstegen
MM, Francies HE, Gavarró LM, Bradshaw CR, Allen GE, Arnes-Benito R,
Sidorova O, Gaspersz MP, et al: Human primary liver cancer-derived
organoid cultures for disease modeling and drug screening. Nat Med.
12:1424–1435. 2017. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gao D, Vela I, Sboner A, Iaquinta PJ,
Karthaus WR, Gopalan A, Dowling C, Wanjala JN, Undvall EA, Arora
VK, et al: Organoid cultures derived from patients with advanced
prostate cancer. Cell. 159:176–187. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ganesh K, Wu C, O'Rourke KP, Szeglin BC,
Zheng Y, Sauvé CG, Adileh M, Wasserman I, Marco MR, Kim AS, et al:
A rectal cancer organoid platform to study individual responses to
chemoradiation. Nat Med. 25:1607–1614. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Romero-Calvo I, Weber CR, Ray M, Brown M,
Kirby K, Nandi RK, Long TM, Sparrow SM, Ugolkov A, Qiang W, et al:
Human organoids share structural and genetic features with primary
pancreatic adenocarcinoma tumors. Mol Cancer Res. 17:70–83. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Saito Y, Muramatsu T, Kanai Y, Ojima H,
Sukeda A, Hiraoka N, Arai E, Sugiyama Y, Matsuzaki J, Uchida R, et
al: Establishment of patient-derived organoids and drug screening
for biliary tract carcinoma. Cell Rep. 27:1265–1276.e4. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lee SH, Hu W, Matulay JT, Silva MV,
Owczarek TB, Kim K, Chua CW, Barlow LJ, Kandoth C, Williams AB, et
al: Tumor evolution and drug response in patient-derived organoid
models of bladder cancer. Cell. 173:515–528.e17. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bilim V, Yuuki K, Itoi T, Muto A, Kato T,
Nagaoka A, Motoyama T and Tomita Y: Double inhibition of XIAP and
Bcl-2 axis is beneficial for retrieving sensitivity of renal cell
cancer to apoptosis. Br J Cancer. 98:941–949. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liston DR and Davis M: Clinically relevant
concentrations of anticancer drugs: A guide for nonclinical
studies. Clin Cancer Res. 23:3489–3498. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kim M, Mun H, Sung CO, Cho EJ, Jeon HJ,
Chun SM, Jung DJ, Shin TH, Jeong GS, Kim DK, et al: Patient-derived
lung cancer organoids as in vitro cancer models for therapeutic
screening. Nat Commun. 10:39912019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Aberle MR, Burkhart RA, Tiriac H, Olde
Damink SW, Dejong CH, Tuveson DA and van Dam RM: Patient-derived
organoid models help define personalized management of
gastrointestinal cancer. Br J Surg. 105:e48–e60. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
van de Wetering M, Francies HE, Francis
JM, Bounova G, Iorio F, Pronk A, van Houdt W, van Gorp J,
Taylor-Weiner A, Kester L, et al: Prospective derivation of a
living organoid biobank of colorectal cancer patients. Cell.
161:933–945. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Grassi L, Alfonsi R, Francescangeli F,
Signore M, De Angelis ML, Addario A, Costantini M, Flex E, Ciolfi
A, Pizzi S, et al: Organoids as a new model for improving
regenerative medicine and cancer personalized therapy in renal
diseases. Cell Death Dis. 10:2012019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Neal JT, Li X, Zhu J, Giangarra V,
Grzeskowiak CL, Ju J, Liu IH, Chiou SH, Salahudeen AA, Smith AR, et
al: Organoid modeling of the tumor immune microenvironment. Cell.
175:1972–1988.e16. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Vlachogiannis G, Hedayat S, Vatsiou A,
Jamin Y, Fernández-Mateos J, Khan K, Lampis A, Eason K, Huntingford
I, Burke R, et al: Patient-derived organoids model treatment
response of metastatic gastrointestinal cancers. Science.
359:920–926. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bian S, Repic M, Guo Z, Kavirayani A,
Burkard T, Bagley JA, Krauditsch C and Knoblich JA: Author
correction: Genetically engineered cerebral organoids model brain
tumor formation. Nat Methods. 15:7482018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Motzer RJ, Penkov K, Haanen J, Rini B,
Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S,
Uemura M, et al: Avelumab plus Axitinib versus Sunitinib for
advanced renal-cell carcinoma. N Engl J Med. 380:1103–1115. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rini BI, Plimack ER, Stus V, Gafanov R,
Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulières D, Melichar B,
et al: KEYNOTE-426 investigators. Pembrolizumab plus Axitinib
versus Sunitinib for advanced renal-cell carcinoma. N Engl J Med.
380:1116–1127. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Motzer RJ, Tannir NM, McDermott DF, Arén
Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P,
Porta C, George S, et al: CheckMate 214 investigators. Nivolumab
plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma.
N Engl J Med. 378:1277–1290. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zerdes I, Tolia M, Tsoukalas N, Mitsis M,
Kardamakis D, Pistevou-Gombaki K, Tsekeris P and Kyrgias G:
Systemic therapy of metastatic renal cell carcinoma: Review of the
current literature. Urologia. 86:3–8. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu C, Qin T, Huang Y, Li Y, Chen G and
Sun C: Drug screening model meets cancer organoid technology.
Transl Oncol. 13:1008402020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li M and Izpisua Belmonte JC:
Organoids-preclinical models of human disease. N Engl J Med.
380:569–579. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bleijs M, van de Wetering M, Clevers H and
Drost J: Xenograft and organoid model systems in cancer research.
EMBO J. 38:e1016542019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Drost J and Clevers H: Organoids in cancer
research. Nat Rev Cancer. 18:407–418. 2018. View Article : Google Scholar : PubMed/NCBI
|
